Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 25

ELITE PHARMACEUTICALS INC /DE/ Form 25 May 11, 2009

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### **FORM 25**

# NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 001-15697

#### Elite Pharmaceuticals, Inc., NYSE AMEX

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed an

### 165 Ludlow Avenue, Northvale, New Jersey 07647 (201) 750-2646

(Address, including zip code, and telephone number, including area code, of Issuer□s principal ex

### Common Stock, par value \$0.01 per share

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

- o 17 CFR 240.12d2 -2(a)(1)
- o 17 CFR 240.12d2 -2(a)(2)
- o 17 CFR 240.12d2 -2(a)(3)
- o 17 CFR 240.12d2 -2(a)(4)
- o Pursuant to 17 CFR 240.12d2 -2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.<sup>1</sup>
- x Pursuant to 17 CFR 240.12d2 -2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2 -2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

### Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 25

Pursuant to the requirements of the Securities Exchange Act of 1934, Elite Pharmaceuticals, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

| May 11, 2009 | By /s/ Chris Dick | Acting Chief Executive Officer |
|--------------|-------------------|--------------------------------|
| Date         | Name              | Title                          |

SEC 1654(03-06) Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

<sup>&</sup>lt;sup>1</sup> Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d -1 as applicable. See General Instructions.